Microglia Lacking E Prostanoid Receptor Subtype 2 Have Enhanced Aβ Phagocytosis yet Lack Aβ-Activated Neurotoxicity

[1]  S. Goodman,et al.  Nonsteroidal Anti-Inflammatory Drugs for the Prevention of Alzheimer’s Disease: A Systematic Review , 2004, Neuroepidemiology.

[2]  D. Aronoff,et al.  Prostaglandin E2 Inhibits Alveolar Macrophage Phagocytosis through an E-Prostanoid 2 Receptor-Mediated Increase in Intracellular Cyclic AMP12 , 2004, The Journal of Immunology.

[3]  B. Sacchetti,et al.  Involvement of the Intracellular Ion Channel CLIC1 in Microglia-Mediated β-Amyloid-Induced Neurotoxicity , 2004, The Journal of Neuroscience.

[4]  M. Ross,et al.  Prostanoids, not reactive oxygen species, mediate COX‐2–dependent neurotoxicity , 2004, Annals of neurology.

[5]  G. Cole,et al.  The microglial phagocytic role with specific plaque types in the Alzheimer disease brain , 2004, Neurobiology of Aging.

[6]  J. Roman,et al.  Suppression of prostaglandin E2 receptor subtype EP2 by PPARgamma ligands inhibits human lung carcinoma cell growth. , 2004, Biochemical and biophysical research communications.

[7]  O. Mitrasinovic,et al.  Microglial overexpression of the M-CSF receptor augments phagocytosis of opsonized Aβ , 2003, Neurobiology of Aging.

[8]  D. Dickson,et al.  Amyloid-β Immunization Effectively Reduces Amyloid Deposition in FcRγ-/- Knock-Out Mice , 2003, The Journal of Neuroscience.

[9]  M. Cathcart,et al.  Protein Kinase C β Is Required for Human Monocyte Chemotaxis to MCP-1* , 2003, Journal of Biological Chemistry.

[10]  P. Mcgeer,et al.  Is there a future for vaccination as a treatment for Alzheimer’s disease? , 2003, Neurobiology of Aging.

[11]  T. Rogers,et al.  Ca2+-independent Protein Kinase Cs Mediate Heterologous Desensitization of Leukocyte Chemokine Receptors by Opioid Receptors* , 2003, The Journal of Biological Chemistry.

[12]  Bin Liu,et al.  Microglia enhance β‐amyloid peptide‐induced toxicity in cortical and mesencephalic neurons by producing reactive oxygen species , 2002 .

[13]  Rena Li,et al.  Microglia and inflammatory mechanisms in the clearance of amyloid β peptide , 2002 .

[14]  A. Minagar,et al.  The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis , 2002, Journal of the Neurological Sciences.

[15]  T. Montine,et al.  Neuronal oxidative damage from activated innate immunity is EP2 receptor‐dependent , 2002, Journal of neurochemistry.

[16]  B. Hyman,et al.  Non-Fc-Mediated Mechanisms Are Involved in Clearance of Amyloid-β In Vivo by Immunotherapy , 2002, The Journal of Neuroscience.

[17]  Tony Wyss-Coray,et al.  Inflammation in Neurodegenerative Disease—A Double-Edged Sword , 2002, Neuron.

[18]  Rong Wang,et al.  A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity , 2001, Nature.

[19]  L. Lue,et al.  Gene expression profiling of amyloid beta peptide-stimulated human post-mortem brain microglia , 2001, Neurobiology of Aging.

[20]  Patrick L. McGeer,et al.  Inflammation, autotoxicity and Alzheimer disease , 2001, Neurobiology of Aging.

[21]  P. Worley,et al.  Age-Dependent Cognitive Deficits and Neuronal Apoptosis in Cyclooxygenase-2 Transgenic Mice , 2001, The Journal of Neuroscience.

[22]  H. Hampel,et al.  Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro , 2001, Glia.

[23]  J. Loike,et al.  Scavenger receptor class B type I (SR-BI) mediates adhesion of neonatal murine microglia to fibrillar β-amyloid , 2001, Journal of Neuroimmunology.

[24]  S. Rivest,et al.  Anti‐inflammatory effects of prostaglandin E2 in the central nervous system in response to brain injury and circulating lipopolysaccharide , 2001, Journal of neurochemistry.

[25]  R. Motter,et al.  Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease , 2000, Nature Medicine.

[26]  C. Plata-salamán,et al.  Inflammation and Alzheimer’s disease , 2000, Neurobiology of Aging.

[27]  J. Rogers,et al.  Key issues in Alzheimer’s disease inflammation , 2000, Neurobiology of Aging.

[28]  G. Landreth,et al.  Inflammatory Mechanisms in Alzheimer's Disease: Inhibition of β-Amyloid-Stimulated Proinflammatory Responses and Neurotoxicity by PPARγ Agonists , 2000, The Journal of Neuroscience.

[29]  T. Montine,et al.  Elevated CSF prostaglandin E2 levels in patients with probable AD. , 1999, Neurology.

[30]  T. Petrova,et al.  Selective modulation of BV-2 microglial activation by prostaglandin E(2). Differential effects on endotoxin-stimulated cytokine induction. , 1999, The Journal of biological chemistry.

[31]  T. Petrova,et al.  Selective Modulation of BV-2 Microglial Activation by Prostaglandin E2 , 1999, The Journal of Biological Chemistry.

[32]  R. Motter,et al.  Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.

[33]  R. P. Kraig,et al.  Prostaglandin E Receptor Subtypes in Cultured Rat Microglia and Their Role in Reducing Lipopolysaccharide‐Induced Interleukin‐1 β Production , 1999, Journal of neurochemistry.

[34]  S. Narumiya,et al.  Prostanoid receptors: structures, properties, and functions. , 1999, Physiological reviews.

[35]  B. Solomon,et al.  Disaggregation of Alzheimer β-amyloid by site-directed mAb , 1997 .

[36]  J. Loike,et al.  Scavenger receptor-mediated adhesion of microglia to β-amyloid fibrils , 1996, Nature.

[37]  Patrick L. McGeer,et al.  Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease , 1996, Neurology.

[38]  T. Dawson,et al.  Nitric oxide in neurodegeneration. , 1998, Progress in brain research.